AH 003
Alternative Names: AH-003; Androgen receptor targeted protein degrader - AnHorn MedicinesLatest Information Update: 20 Dec 2023
At a glance
- Originator AnHorn Medicines
- Class Antineoplastics
- Mechanism of Action Ubiquitin protein ligase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 20 Dec 2023 AH 003 is available for licensing as of 20 Dec 2023. https://www.anhornmed.com/focus-area/#Pipelines
- 20 Dec 2023 Preclinical trials in Prostate cancer in Taiwan (unspecified route), prior to December 2023 (AnHorn Medicines pipeline, December 2023)
- 21 Jul 2023 Early research in Prostate cancer in Taiwan prior to July 2023 (AnHorn Medicines pipeline, July 2023)